According to the study by researchers from the Indian Council of Medical Research (ICMR), drug-resistant diseases not only lengthen hospital stays but also raise treatment expenses by 33.1%.
Common infections are more difficult to cure, result in more hospitalizations and longer hospital stays, and cause more complications due to antimicrobial resistance, which is the ability of pathogens to persist and cause disease even in the presence of antimicrobial medications.
One of the first studies from India to examine the expense of treating resistant illnesses in both public and private hospitals is this one. As families borrow money, deplete their savings, and sell or mortgage assets to pay for therapy, the study also examines the resulting economic hardship.
In comparison to drug-susceptible infections, the average cost of treating resistant infections increased by 33.1%, according to a study that examined 1,723 patient data from eight different hospitals. According to the study, the average cost of treating resistant infections was $1,238 and for sensitive infections, it was $827. In government hospitals, treating susceptible infections cost $108.5, but treating resistant infections cost $199.2. In private hospitals, treating susceptible infections cost $3,019, while treating resistant infections cost $3,382.
Researchers discovered that the expense of treating resistant infections was primarily driven by the cost of medications. The cost of medications rose by 61.5% in government hospitals and 27.1% in private hospitals, although the costs of hospital stays, investigations, and consumables were about the same for both groups.
Additionally, the study revealed that individuals with resistant infections typically spent 23 days in hospitals, whereas those with susceptible illnesses only spent 12 days.
Higher mortality was also a result of resistant infections. According to the study, compared to 20% of people with susceptible illnesses, 29.5% of those with resistant infections passed away.
Regardless of the kind of infection, the survey discovered that more than 45% of patients took out loans to pay for their care. Those with resistant infections were more likely to borrow—47.6% versus 44.6% for those with susceptible infections.
Additionally, the study discovered that in 10.5% of instances with resistant infections, compared to 6.2% with susceptible illnesses, a family member began working or the children were pulled out of school. Those with resistant infections were also more likely to sell or mortgage their possessions (11.4%) than those with susceptible diseases (9.8%).
In order to avoid both financial hardship and fatalities, the researchers argue in this paper that treatment resistance in microorganisms should be prevented. Given that out-of-pocket expenses accounted for over 70% of household health spending, the increased costs associated with treating resistant diseases may cause financial hardship. The mortality rate is also expected to decrease with the reduction of resistant diseases.
Experts advise that individuals should be made aware of the fact that high exposure to antibiotics is increasing resistance so they do not take antibiotics without a prescription, stop their treatment in the middle, or give their medication to others. By avoiding wide spectrum medicines or switching to more tailored ones after testing for the illness, doctors can also help.
In order to prevent antibiotics from being released into the environment, businesses must also make sure they handle solid and wastewater waste properly.
-NSH Digidesk
